Health Score

0 Good

Metadata coverage

Abstract

ORCID

References

License

Extended metadata coverage

Informational — signals of interoperability and funding across the corpus. Not part of the health score.

Funding

Funder

Award / grant

Affiliation & institutional identifiers

Affiliation

ROR ID

Update policy

Your prioritized action plan

Ordered by how many DOIs each fix touches — start here, not with every error at once.

Attach ORCID iDs across 222 articles

ORCID iDs strengthen author disambiguation and institutional reporting.

Medium impact222 DOIs

Add abstracts to 127 articles

Abstracts are what surface your work in Google Scholar, Dimensions, and OpenAlex.

Low impact127 DOIs

Deposit reference lists for 122 records

Deposited references power Crossref's Cited-by links between your articles and the literature.

Low impact122 DOIs

DOIs for this ISSN

Showing the top 5 of 495 DOIs, ordered by correction priority.

#	Title	Missing	Priority	Citations
1	Optimized p53 immunohistochemistry is an accurate predictor… (10.1002/cjp2.53)	ORCID	63.97	361
2	Circulating human papillomavirus DNA detected using droplet… (10.1002/cjp2.47)	ORCID	55.24	161
3	Diagnostic value of <i>H3F3A</i> mutations in giant cell tum… (10.1002/cjp2.13)	ORCID	54.18	146
4	In‐depth molecular profiling of the biphasic components of u… (10.1002/cjp2.18)	ORCID	49.33	93
5	Gene expression profiling of <scp>E</scp>wing sarcoma tumour… (10.1002/cjp2.9)	ORCID	49.09	91
6	Classical pathology and mutational load of breast cancer – i… (10.1002/cjp2.25)	ORCID	48.61	87
7	The molecular background of mucinous carcinoma beyond MUC2 (10.1002/cjp2.1)	ORCID	47.02	75
8	Increased MMP‐7 expression in biliary epithelium and serum u… (10.1002/cjp2.50)	ORCID	46.58	72
9	Immunoscore in mismatch repair‐proficient and ‐deficient col… (10.1002/cjp2.71)	ORCID	45.97	68
10	Cancer‐testis antigens PRAME and NY‐ESO‐1 correlate with tum… (10.1002/cjp2.16)	ORCID	45.49	65
11	The pathology and pathobiology of bicuspid aortic valve: Sta… (10.1002/cjp2.21)	ORCID	45.15	63
12	Gene expression analysis of biopsy samples reveals critical… (10.1002/cjp2.37)	ORCID	45.15	63
13	The prognosis of <i>MYC</i> translocation positive diffuse l… (10.1002/cjp2.10)	ORCID	43.70	55
14	Current status of clinical testing for human papillomavirus… (10.1002/cjp2.111)	ORCID	43.31	53
15	The infiltration, and prognostic importance, of Th1 lymphocy… (10.1002/cjp2.31)	ORCID	42.90	51
16	Frequent alterations in p16/<i>CDKN2A</i> identified by immu… (10.1002/cjp2.156)	ORCID	42.25	48
17	Molecular classification of thyroid lesions by combined test… (10.1002/cjp2.38)	ORCID	42.25	48
18	STAT1‐associated intratumoural T<sub>H</sub>1 immunity predi… (10.1002/cjp2.55)	ORCID	41.80	46
19	Increased proliferation in atypical hyperplasia/endometrioid… (10.1002/cjp2.22)	ORCID	41.57	45
20	<scp>KLF2</scp> inhibits colorectal cancer progression and m… (10.1002/cjp2.325)	ORCID	41.57	45
21	Fluorescence imaging to localize head and neck squamous cell… (10.1002/cjp2.40)	ORCID	41.33	44
22	Fluorescence <i>in situ</i> hybridization in surgical pathol… (10.1002/cjp2.64)	ORCID	41.09	43
23	Loss of ATRX and DAXX expression identifies poor prognosis f… (10.1002/cjp2.11)	ORCID	40.84	42
24	An analysis of <scp>HER2</scp> amplification in cervical ade… (10.1002/cjp2.184)	ORCID	40.84	42
25	Comparative analysis of morphological and molecular motifs i… (10.1002/cjp2.60)	ORCID	40.32	40
26	High expression of stromal PDGFRβ is associated with reduced… (10.1002/cjp2.56)	ORCID	40.05	39
27	Construction and analysis of tissue microarrays in the era o… (10.1002/cjp2.62)	ORCID	40.05	39
28	FGFR1, 2 and 3 protein overexpression and molecular aberrati… (10.1002/cjp2.51)	ORCID	39.78	38
29	Sarcoma and the 100,000 Genomes Project: our experience and… (10.1002/cjp2.174)	ORCID	39.21	36
30	Nottingham Prognostic Index Plus: Validation of a clinical d… (10.1002/cjp2.32)	ORCID	38.60	34
31	FOXC2 expression and epithelial–mesenchymal phenotypes are a… (10.1002/cjp2.142)	ORCID	38.29	33
32	Regulation of macroautophagy in amiodarone‐induced pulmonary… (10.1002/cjp2.20)	ORCID	38.29	33
33	Somatic mutation in <i>PIK3CA</i> is a late event in cervica… (10.1002/cjp2.27)	ORCID	37.63	31
34	Novel translational model of resolving inflammation triggere… (10.1002/cjp2.43)	ORCID	37.28	30
35	<i>PLA2G7</i> associates with hormone receptor negativity in… (10.1002/cjp2.69)	ORCID	37.28	30
36	The epithelial–mesenchymal transition regulators Twist, Slug… (10.1002/cjp2.202)	ORCID	36.93	29
37	The molecular landscape of extraskeletal osteosarcoma: A cli… (10.1002/cjp2.29)	ORCID	36.18	27
38	FMNL2/FMNL3 formins are linked with oncogenic pathways and p… (10.1002/cjp2.34)	ORCID	36.18	27
39	High CerS5 expression levels associate with reduced patient… (10.1002/cjp2.5)	ORCID	36.18	27
40	Pulmonary adenocarcinoma with mucin production modulates phe… (10.1002/cjp2.67)	ORCID	35.37	25
41	Performance of automated scoring of ER, PR, HER2, CK5/6 and… (10.1002/cjp2.3)	ORCID	34.95	24
42	Lupus nephritis: low urinary DNase I levels reflect loss of… (10.1002/cjp2.99)	ORCID	34.95	24
43	A combined biomarker and clinical panel for chronic graft ve… (10.1002/cjp2.58)	ORCID	34.51	23
44	Significance of tumour regression in lymph node metastases o… (10.1002/cjp2.169)	ORCID	34.04	22
45	Inflammatory response in serrated precursor lesions of the c… (10.1002/cjp2.41)	ORCID	34.04	22
46	<scp>TFE3</scp> activation in a <scp><i>TSC1</i>‐altered</sc… (10.1002/cjp2.187)	ORCID	33.56	21
47	Differential expression of argininosuccinate synthetase in s… (10.1002/cjp2.4)	ORCID	33.56	21
48	<i>KRAS</i> mutation in papillary fibroelastoma: a true card… (10.1002/cjp2.66)	ORCID	33.56	21
49	Next generation sequencing of the nidus of early (adenosquam… (10.1002/cjp2.68)	ORCID	33.56	21
50	ERCC1 and telomere status in breast tumours treated with neo… (10.1002/cjp2.52)	ORCID	33.06	20